The risk of thrombo-embolic events is increased in patients with germ-cell tumours and can be predicted by serum lactate dehydrogenase ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2005-10-04

AUTHORS

A-C Piketty, A Fléchon, A Laplanche, E Nouyrigat, J-P Droz, C Théodore, K Fizazi

ABSTRACT

The aim of this study was to evaluate the risk of thrombo-embolic events (TEE) in patients with germ-cell tumours (GCT) who receive cisplatin-based chemotherapy, to compare this risk to that of a matched control group of non-GCT cancer patients, and to identify risk factors of TEE. The rate of TEE during the 6 months following the initiation of chemotherapy was assessed in 100 consecutive patients with GCT and in 100 controls with various neoplasms who were matched on sex and age, and who received first-line cisplatin-based chemotherapy during the same period of time at Institut Gustave Roussy, Villejuif, France. Data were subsequently tested on a validation group of 77 GCT patients treated in Lyon, France. A total of 19 patients (19%) (95% confidence interval (CI): 13–28) and six patients (6%) (95% CI: 3–13) had a TEE in the GCT group and the non-GCT control group, respectively (relative risk (RR): 3.4; P<0.01). Three patients from the GCT group died of pulmonary embolism. In multivariate analysis, two factors had independent predictive value for TEE: a high body surface area (>1.9 m2) (RR: 5 (1.8–13.9)) and an elevated serum lactate dehydrogenase (LDH) (RR: 6.4 (2.3–18.2)). Patients with no risk factor (n=26) and those with at least one risk factor (n=71) had a probability of having a TEE of 4% (95% CI: 1–19) and 26% (95% CI: 17–37), respectively. In the GCT validation set, 10 (13%) patients had a TEE; patients with no risk factor and those with at least one risk factor had a probability of having a TEE of 0 and 17% (95% CI: 10–29), respectively. Patients with GCT are at a higher risk for TEE than patients with non-GCT cancer while on cisplatin-based chemotherapy. This risk can be accurately predicted by serum LDH and body surface area. This predictive index may help to study prospectively the impact of thromboprophylaxis in GCT patients. More... »

PAGES

909-914

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/sj.bjc.6602791

DOI

http://dx.doi.org/10.1038/sj.bjc.6602791

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1008053784

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/16205699


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adolescent", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Biomarkers", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Body Surface Area", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Case-Control Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cisplatin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "L-Lactate Dehydrogenase", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasms, Germ Cell and Embryonal", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Predictive Value of Tests", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Risk Factors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Thromboembolism", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Centre L\u00e9on B\u00e9rard, Lyon, France", 
          "id": "http://www.grid.ac/institutes/grid.418116.b", 
          "name": [
            "Institut Gustave Roussy, Villejuif, France", 
            "Centre L\u00e9on B\u00e9rard, Lyon, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Piketty", 
        "givenName": "A-C", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre L\u00e9on B\u00e9rard, Lyon, France", 
          "id": "http://www.grid.ac/institutes/grid.418116.b", 
          "name": [
            "Institut Gustave Roussy, Villejuif, France", 
            "Centre L\u00e9on B\u00e9rard, Lyon, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fl\u00e9chon", 
        "givenName": "A", 
        "id": "sg:person.0651426070.32", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0651426070.32"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre L\u00e9on B\u00e9rard, Lyon, France", 
          "id": "http://www.grid.ac/institutes/grid.418116.b", 
          "name": [
            "Institut Gustave Roussy, Villejuif, France", 
            "Centre L\u00e9on B\u00e9rard, Lyon, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Laplanche", 
        "givenName": "A", 
        "id": "sg:person.01315625314.27", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01315625314.27"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre L\u00e9on B\u00e9rard, Lyon, France", 
          "id": "http://www.grid.ac/institutes/grid.418116.b", 
          "name": [
            "Institut Gustave Roussy, Villejuif, France", 
            "Centre L\u00e9on B\u00e9rard, Lyon, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nouyrigat", 
        "givenName": "E", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre L\u00e9on B\u00e9rard, Lyon, France", 
          "id": "http://www.grid.ac/institutes/grid.418116.b", 
          "name": [
            "Institut Gustave Roussy, Villejuif, France", 
            "Centre L\u00e9on B\u00e9rard, Lyon, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Droz", 
        "givenName": "J-P", 
        "id": "sg:person.016263346364.52", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016263346364.52"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre L\u00e9on B\u00e9rard, Lyon, France", 
          "id": "http://www.grid.ac/institutes/grid.418116.b", 
          "name": [
            "Institut Gustave Roussy, Villejuif, France", 
            "Centre L\u00e9on B\u00e9rard, Lyon, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Th\u00e9odore", 
        "givenName": "C", 
        "id": "sg:person.013607432017.21", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013607432017.21"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre L\u00e9on B\u00e9rard, Lyon, France", 
          "id": "http://www.grid.ac/institutes/grid.418116.b", 
          "name": [
            "Institut Gustave Roussy, Villejuif, France", 
            "Centre L\u00e9on B\u00e9rard, Lyon, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fizazi", 
        "givenName": "K", 
        "id": "sg:person.01126535135.46", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01126535135.46"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1385/mo:20:2:189", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009300191", 
          "https://doi.org/10.1385/mo:20:2:189"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.1977.1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027080276", 
          "https://doi.org/10.1038/bjc.1977.1"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2005-10-04", 
    "datePublishedReg": "2005-10-04", 
    "description": "The aim of this study was to evaluate the risk of thrombo-embolic events (TEE) in patients with germ-cell tumours (GCT) who receive cisplatin-based chemotherapy, to compare this risk to that of a matched control group of non-GCT cancer patients, and to identify risk factors of TEE. The rate of TEE during the 6 months following the initiation of chemotherapy was assessed in 100 consecutive patients with GCT and in 100 controls with various neoplasms who were matched on sex and age, and who received first-line cisplatin-based chemotherapy during the same period of time at Institut Gustave Roussy, Villejuif, France. Data were subsequently tested on a validation group of 77 GCT patients treated in Lyon, France. A total of 19 patients (19%) (95% confidence interval (CI): 13\u201328) and six patients (6%) (95% CI: 3\u201313) had a TEE in the GCT group and the non-GCT control group, respectively (relative risk (RR): 3.4; P<0.01). Three patients from the GCT group died of pulmonary embolism. In multivariate analysis, two factors had independent predictive value for TEE: a high body surface area (>1.9\u2009m2) (RR: 5 (1.8\u201313.9)) and an elevated serum lactate dehydrogenase (LDH) (RR: 6.4 (2.3\u201318.2)). Patients with no risk factor (n=26) and those with at least one risk factor (n=71) had a probability of having a TEE of 4% (95% CI: 1\u201319) and 26% (95% CI: 17\u201337), respectively. In the GCT validation set, 10 (13%) patients had a TEE; patients with no risk factor and those with at least one risk factor had a probability of having a TEE of 0 and 17% (95% CI: 10\u201329), respectively. Patients with GCT are at a higher risk for TEE than patients with non-GCT cancer while on cisplatin-based chemotherapy. This risk can be accurately predicted by serum LDH and body surface area. This predictive index may help to study prospectively the impact of thromboprophylaxis in GCT patients.", 
    "genre": "article", 
    "id": "sg:pub.10.1038/sj.bjc.6602791", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1017082", 
        "issn": [
          "0007-0920", 
          "1532-1827"
        ], 
        "name": "British Journal of Cancer", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "8", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "93"
      }
    ], 
    "keywords": [
      "thrombo-embolic events", 
      "germ cell tumors", 
      "cisplatin-based chemotherapy", 
      "serum lactate dehydrogenase", 
      "body surface area", 
      "risk factors", 
      "GCT patients", 
      "lactate dehydrogenase", 
      "GCT group", 
      "first-line cisplatin-based chemotherapy", 
      "control group", 
      "elevated serum lactate dehydrogenase", 
      "impact of thromboprophylaxis", 
      "initiation of chemotherapy", 
      "higher body surface area", 
      "independent predictive value", 
      "Institut Gustave Roussy", 
      "pulmonary embolism", 
      "consecutive patients", 
      "cancer patients", 
      "Gustave Roussy", 
      "high risk", 
      "patients", 
      "predictive value", 
      "chemotherapy", 
      "validation group", 
      "multivariate analysis", 
      "predictive index", 
      "risk", 
      "tumors", 
      "same period", 
      "group", 
      "validation set", 
      "thromboprophylaxis", 
      "embolism", 
      "factors", 
      "neoplasms", 
      "Roussy", 
      "cancer", 
      "Villejuif", 
      "months", 
      "age", 
      "sex", 
      "dehydrogenase", 
      "total", 
      "events", 
      "aim", 
      "initiation", 
      "index", 
      "period", 
      "control", 
      "study", 
      "area", 
      "rate", 
      "data", 
      "France", 
      "time", 
      "impact", 
      "analysis", 
      "probability", 
      "surface area", 
      "values", 
      "Lyon", 
      "set"
    ], 
    "name": "The risk of thrombo-embolic events is increased in patients with germ-cell tumours and can be predicted by serum lactate dehydrogenase and body surface area", 
    "pagination": "909-914", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1008053784"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/sj.bjc.6602791"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "16205699"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/sj.bjc.6602791", 
      "https://app.dimensions.ai/details/publication/pub.1008053784"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-10-01T06:33", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/article/article_411.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1038/sj.bjc.6602791"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/sj.bjc.6602791'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/sj.bjc.6602791'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/sj.bjc.6602791'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/sj.bjc.6602791'


 

This table displays all metadata directly associated to this object as RDF triples.

238 TRIPLES      21 PREDICATES      107 URIs      97 LITERALS      23 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/sj.bjc.6602791 schema:about N09860c16df2840db87404179d8a618a8
2 N20ad2f78b74e4c6682338f397f81da13
3 N224b10b0daab471a8b156588acc97a3d
4 N36e06c64b5054e63941afebe36252bf5
5 N371c1c4b09634a5faedf5672f5cf5efe
6 N46a382446b1f46229252ebf9d61a34d7
7 N5260222b3de54f5bbaf12c4da522150b
8 N756ec5532b774c8d9b6843084672e066
9 N79023c40cc25476cbbcef99408b75173
10 N85e22fc5b1ed4833a493a4d6f96f1cd2
11 Nb68cf37957d14ace82adca071fcf05a0
12 Nba43d0c17f234de38373ba695b035f40
13 Nbf64073d5ff8439e8caed150525aacb0
14 Nbfd29ca59ccf486f9e24e9612c0a5e30
15 Nce2f948a1b2442819e145fc81d92a525
16 Nfd1bb873ce4442068374be35d3e484c5
17 anzsrc-for:11
18 anzsrc-for:1112
19 schema:author N15aacff1581746a48079afd8b14de2c9
20 schema:citation sg:pub.10.1038/bjc.1977.1
21 sg:pub.10.1385/mo:20:2:189
22 schema:datePublished 2005-10-04
23 schema:datePublishedReg 2005-10-04
24 schema:description The aim of this study was to evaluate the risk of thrombo-embolic events (TEE) in patients with germ-cell tumours (GCT) who receive cisplatin-based chemotherapy, to compare this risk to that of a matched control group of non-GCT cancer patients, and to identify risk factors of TEE. The rate of TEE during the 6 months following the initiation of chemotherapy was assessed in 100 consecutive patients with GCT and in 100 controls with various neoplasms who were matched on sex and age, and who received first-line cisplatin-based chemotherapy during the same period of time at Institut Gustave Roussy, Villejuif, France. Data were subsequently tested on a validation group of 77 GCT patients treated in Lyon, France. A total of 19 patients (19%) (95% confidence interval (CI): 13–28) and six patients (6%) (95% CI: 3–13) had a TEE in the GCT group and the non-GCT control group, respectively (relative risk (RR): 3.4; P<0.01). Three patients from the GCT group died of pulmonary embolism. In multivariate analysis, two factors had independent predictive value for TEE: a high body surface area (>1.9 m2) (RR: 5 (1.8–13.9)) and an elevated serum lactate dehydrogenase (LDH) (RR: 6.4 (2.3–18.2)). Patients with no risk factor (n=26) and those with at least one risk factor (n=71) had a probability of having a TEE of 4% (95% CI: 1–19) and 26% (95% CI: 17–37), respectively. In the GCT validation set, 10 (13%) patients had a TEE; patients with no risk factor and those with at least one risk factor had a probability of having a TEE of 0 and 17% (95% CI: 10–29), respectively. Patients with GCT are at a higher risk for TEE than patients with non-GCT cancer while on cisplatin-based chemotherapy. This risk can be accurately predicted by serum LDH and body surface area. This predictive index may help to study prospectively the impact of thromboprophylaxis in GCT patients.
25 schema:genre article
26 schema:isAccessibleForFree true
27 schema:isPartOf N218a996730344de5a4e6b845d14df40e
28 Na52e58888c314802b0ecf7b6b53e4a9e
29 sg:journal.1017082
30 schema:keywords France
31 GCT group
32 GCT patients
33 Gustave Roussy
34 Institut Gustave Roussy
35 Lyon
36 Roussy
37 Villejuif
38 age
39 aim
40 analysis
41 area
42 body surface area
43 cancer
44 cancer patients
45 chemotherapy
46 cisplatin-based chemotherapy
47 consecutive patients
48 control
49 control group
50 data
51 dehydrogenase
52 elevated serum lactate dehydrogenase
53 embolism
54 events
55 factors
56 first-line cisplatin-based chemotherapy
57 germ cell tumors
58 group
59 high risk
60 higher body surface area
61 impact
62 impact of thromboprophylaxis
63 independent predictive value
64 index
65 initiation
66 initiation of chemotherapy
67 lactate dehydrogenase
68 months
69 multivariate analysis
70 neoplasms
71 patients
72 period
73 predictive index
74 predictive value
75 probability
76 pulmonary embolism
77 rate
78 risk
79 risk factors
80 same period
81 serum lactate dehydrogenase
82 set
83 sex
84 study
85 surface area
86 thrombo-embolic events
87 thromboprophylaxis
88 time
89 total
90 tumors
91 validation group
92 validation set
93 values
94 schema:name The risk of thrombo-embolic events is increased in patients with germ-cell tumours and can be predicted by serum lactate dehydrogenase and body surface area
95 schema:pagination 909-914
96 schema:productId N41833dec8c9b45dea12b86be5a432af2
97 N9872e1f6bbb64d4391195f9b98a73bd3
98 Ne478c22d93144cfeb073537393994597
99 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008053784
100 https://doi.org/10.1038/sj.bjc.6602791
101 schema:sdDatePublished 2022-10-01T06:33
102 schema:sdLicense https://scigraph.springernature.com/explorer/license/
103 schema:sdPublisher Nfe4f29b167b948cf9f5cac62ad7bff70
104 schema:url https://doi.org/10.1038/sj.bjc.6602791
105 sgo:license sg:explorer/license/
106 sgo:sdDataset articles
107 rdf:type schema:ScholarlyArticle
108 N09860c16df2840db87404179d8a618a8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
109 schema:name Neoplasms, Germ Cell and Embryonal
110 rdf:type schema:DefinedTerm
111 N0ab1a03b302f4e95ad06291e6e1871e8 rdf:first N7adde732b58f45f296ef5f469bb184d8
112 rdf:rest N7b3fae7217b44c7ab1af96a97ff10927
113 N1556b2a5383a4f03803011383e78b89f rdf:first sg:person.0651426070.32
114 rdf:rest N98fc402bdc9e405f9e63e45cadfe043e
115 N15aacff1581746a48079afd8b14de2c9 rdf:first Nde9592b635a241dcbdbed0850fb005cf
116 rdf:rest N1556b2a5383a4f03803011383e78b89f
117 N20ad2f78b74e4c6682338f397f81da13 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
118 schema:name Case-Control Studies
119 rdf:type schema:DefinedTerm
120 N218a996730344de5a4e6b845d14df40e schema:volumeNumber 93
121 rdf:type schema:PublicationVolume
122 N224b10b0daab471a8b156588acc97a3d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
123 schema:name Adolescent
124 rdf:type schema:DefinedTerm
125 N36e06c64b5054e63941afebe36252bf5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Antineoplastic Agents
127 rdf:type schema:DefinedTerm
128 N371c1c4b09634a5faedf5672f5cf5efe schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Male
130 rdf:type schema:DefinedTerm
131 N41833dec8c9b45dea12b86be5a432af2 schema:name doi
132 schema:value 10.1038/sj.bjc.6602791
133 rdf:type schema:PropertyValue
134 N46a382446b1f46229252ebf9d61a34d7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name Humans
136 rdf:type schema:DefinedTerm
137 N46c1ccd4cf114a43b7056d4104676077 rdf:first sg:person.013607432017.21
138 rdf:rest Nf9744be8848441f8a3b0b3304510ff4b
139 N5260222b3de54f5bbaf12c4da522150b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Biomarkers
141 rdf:type schema:DefinedTerm
142 N756ec5532b774c8d9b6843084672e066 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Adult
144 rdf:type schema:DefinedTerm
145 N79023c40cc25476cbbcef99408b75173 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name Female
147 rdf:type schema:DefinedTerm
148 N7adde732b58f45f296ef5f469bb184d8 schema:affiliation grid-institutes:grid.418116.b
149 schema:familyName Nouyrigat
150 schema:givenName E
151 rdf:type schema:Person
152 N7b3fae7217b44c7ab1af96a97ff10927 rdf:first sg:person.016263346364.52
153 rdf:rest N46c1ccd4cf114a43b7056d4104676077
154 N85e22fc5b1ed4833a493a4d6f96f1cd2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Risk Factors
156 rdf:type schema:DefinedTerm
157 N9872e1f6bbb64d4391195f9b98a73bd3 schema:name pubmed_id
158 schema:value 16205699
159 rdf:type schema:PropertyValue
160 N98fc402bdc9e405f9e63e45cadfe043e rdf:first sg:person.01315625314.27
161 rdf:rest N0ab1a03b302f4e95ad06291e6e1871e8
162 Na52e58888c314802b0ecf7b6b53e4a9e schema:issueNumber 8
163 rdf:type schema:PublicationIssue
164 Nb68cf37957d14ace82adca071fcf05a0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
165 schema:name Predictive Value of Tests
166 rdf:type schema:DefinedTerm
167 Nba43d0c17f234de38373ba695b035f40 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
168 schema:name L-Lactate Dehydrogenase
169 rdf:type schema:DefinedTerm
170 Nbf64073d5ff8439e8caed150525aacb0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
171 schema:name Cisplatin
172 rdf:type schema:DefinedTerm
173 Nbfd29ca59ccf486f9e24e9612c0a5e30 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
174 schema:name Body Surface Area
175 rdf:type schema:DefinedTerm
176 Nce2f948a1b2442819e145fc81d92a525 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
177 schema:name Thromboembolism
178 rdf:type schema:DefinedTerm
179 Nde9592b635a241dcbdbed0850fb005cf schema:affiliation grid-institutes:grid.418116.b
180 schema:familyName Piketty
181 schema:givenName A-C
182 rdf:type schema:Person
183 Ne478c22d93144cfeb073537393994597 schema:name dimensions_id
184 schema:value pub.1008053784
185 rdf:type schema:PropertyValue
186 Nf9744be8848441f8a3b0b3304510ff4b rdf:first sg:person.01126535135.46
187 rdf:rest rdf:nil
188 Nfd1bb873ce4442068374be35d3e484c5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
189 schema:name Middle Aged
190 rdf:type schema:DefinedTerm
191 Nfe4f29b167b948cf9f5cac62ad7bff70 schema:name Springer Nature - SN SciGraph project
192 rdf:type schema:Organization
193 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
194 schema:name Medical and Health Sciences
195 rdf:type schema:DefinedTerm
196 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
197 schema:name Oncology and Carcinogenesis
198 rdf:type schema:DefinedTerm
199 sg:journal.1017082 schema:issn 0007-0920
200 1532-1827
201 schema:name British Journal of Cancer
202 schema:publisher Springer Nature
203 rdf:type schema:Periodical
204 sg:person.01126535135.46 schema:affiliation grid-institutes:grid.418116.b
205 schema:familyName Fizazi
206 schema:givenName K
207 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01126535135.46
208 rdf:type schema:Person
209 sg:person.01315625314.27 schema:affiliation grid-institutes:grid.418116.b
210 schema:familyName Laplanche
211 schema:givenName A
212 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01315625314.27
213 rdf:type schema:Person
214 sg:person.013607432017.21 schema:affiliation grid-institutes:grid.418116.b
215 schema:familyName Théodore
216 schema:givenName C
217 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013607432017.21
218 rdf:type schema:Person
219 sg:person.016263346364.52 schema:affiliation grid-institutes:grid.418116.b
220 schema:familyName Droz
221 schema:givenName J-P
222 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016263346364.52
223 rdf:type schema:Person
224 sg:person.0651426070.32 schema:affiliation grid-institutes:grid.418116.b
225 schema:familyName Fléchon
226 schema:givenName A
227 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0651426070.32
228 rdf:type schema:Person
229 sg:pub.10.1038/bjc.1977.1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027080276
230 https://doi.org/10.1038/bjc.1977.1
231 rdf:type schema:CreativeWork
232 sg:pub.10.1385/mo:20:2:189 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009300191
233 https://doi.org/10.1385/mo:20:2:189
234 rdf:type schema:CreativeWork
235 grid-institutes:grid.418116.b schema:alternateName Centre Léon Bérard, Lyon, France
236 schema:name Centre Léon Bérard, Lyon, France
237 Institut Gustave Roussy, Villejuif, France
238 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...